NCT06819917Recruiting
Identification of Liver Fibrosis Biomarkers
Prospective Sample Collection Study for Discovery and Evaluation of Novel Blood Based Biomarkers for Assessment of Hepatic Fibrosis
Source: ClinicalTrials.gov · Last updated 27 May 2026
Brief summary (registry, in English)
Chronic liver disease (CLD) is a major cause of global mortality and morbidity . CLD patients are at an increased risk of developing liver fibrosis (formation of scar tissue), cirrhosis and liver failure and are at significant risk to develop primary liver cancer. Non-alcoholic fatty liver disease (NAFLD) represents a major risk for CLD and it is becoming the most common chronic liver condition with an estimated 25% global prevalence. Progression to non-alcoholic steatohepatitis (NASH) occurs in approx. 1 of 5 NAFLD patients and due to the rapidly rising etiology of end-stage liver disease, is currently the second most common etiology of hepatocellular carcinoma (HCC) requiring liver transplantation. Liver biopsy, currently the gold-standard for grading disease activity and staging fibrosis, is invasive, costly and at risk for sampling error. Due to the number of patients diagnosed with fibrosis and since fibrosis stage is prognostic of mortality and drives patient management, it is important to develop noninvasive yet accurate diagnostic tools that can identify fibrosis stage. The purpose of this study is to obtain a panel of clinically well characterized blood specimens to identify novel biomarkers to be used as an aid in diagnosis to assess the stage of clinically significant hepatic fibrosis in patients with signs or symptoms of NAFLD (NAFL/NASH). In addition, quantitative ultrasound (QUS) based approaches combined with artificial intelligence (AI) algorithms will be explored for assessing the stage of fibrosis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 575 (estimated)
- First submitted
- 22 Jan 2025
- Start date
- 1 Feb 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- Roche Diagnostics GmbH
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06819917
What you commit to
- Study type: Observational
- Planned participants: 575
- From 1 Feb 2025 to the primary completion date, Dec 2026
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior liver transplant
Other illness
- Vulnerable person: person deprived of liberty by a judicial or administrative decision and/or person under psychiatric care
- Disease related to other etiologies, including alcoholic liver disease (alcoholic steatohepatitis), MetALD, specific etiology SLD (e.g. DILI or monogenic disease), cryptogenic SLD, viral hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, human immunodeficiency virus, Wilson's disease, Hemochromatosis, alpha-1 antitrypsin deficiency
- Evidence of any other unstable or, untreated clinically significant immunological, neoplastic, endocrine, haematological, gastrointestinal, neurological or psychiatric disorder. Medically controlled comorbidities can be allowed
- Recent myocardial infarction (within last 6 months)
Other
- Self-reported pregnancy or lactating females
- Any type of carcinoma, unless it is at least 5 years in remission
- Self-reported alcohol consumption greater 30 g/day (males) 20 g/day (females)
- Inability to have a liver biopsy, or provide blood sample in a fasted status
- F0-F2 recalled patients with +/- 5% change in weight between the biopsy and study inclusion
Who the study is looking for
- Patients scheduled for biopsy (or F0-F2 patients that underwent biopsy within the last 6 months but at least 1 month ago) suspected of having hepatic fibrosis due to NAFLD (NAFL/NASH) or patients with MASLD or MASH
- Any FIB-4 value available
- Any Fibroscan value available
- Written and signed informed consent present
- Patients aged ≥ 18 years to ≤ 75 years at the time of the blood draw
- Body Mass Index (BMI) ≤ 45 kg/m²
Age in the registry: 18 years to 75 years · Sex: All
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitätsmedizin der Johannes Gutenberg-Universität Mainz Coordinator of this site? Confirm its status | Mainz | Germany | Recruiting |
| Hvidovre Hospital Coordinator of this site? Confirm its status | Copenhagen | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.